AstraZeneca (AZN) Price & Analysis

Compare

6,997 Followers

AZN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$61.24 - $87.68

Previous CloseN/A

Volume1.80M

Average Volume (3M)6.44M

Market Cap

$212.97B

Enterprise ValueN/A

Total Cash (Recent Filing)$5.39B

Total Debt (Recent Filing)$31.29B

Price to Earnings (P/E)27.4

Beta0.39

Next Earnings

Jul 24, 2025

EPS Estimate

1.1

Last Dividend Ex-Date

Feb 21, 2025

Dividend Yield2.21%

Share Statistics

EPS (TTM)1.25

Shares Outstanding3,101,276,900

10 Day Avg. Volume5,253,441

30 Day Avg. Volume6,439,960

Financial Highlights & Ratios

PEG Ratio-4.99

Price to Book (P/B)10.94

Price to Sales (P/S)0.00

P/FCF Ratio49.16

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$87.34

Price Target Upside25.33% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

---

AstraZeneca News

---

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe initiation of a Phase 3 trial in endometrial cancer for puxitatug samrotecan could drive future growth potential in the oncology pipeline.

Product PerformanceEnhertu's 17% increase in sales and its demonstrated improvement in progression-free survival in clinical trials enhance its market position and growth prospects.

Product PipelineAZN's promising new products and pipeline in large, high-growth markets support a strong outlook compared to the pharma sector average.

Bears Say

China Market RisksInvestor concerns are heightened due to risks to the China business arising from alleged improper practices by former employees.

Product SalesThe company reported Total Product Sales below consensus estimates by approximately 2%, raising concerns about revenue performance.

Regulatory ChallengesThe discontinuation of the CAPItello-280 Phase 3 trial raises questions about the future of certain oncology treatments.

---

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

―

Insiders

5.74% Mutual Funds

5.89% Other Institutional Investors

87.47% Public Companies and Individual Investors

Detailed Ownership Overview >

AZN FAQ

What was Astrazeneca Plc’s price range in the past 12 months?

Astrazeneca Plc lowest stock price was $61.24 and its highest was $87.67 in the past 12 months.

What is Astrazeneca Plc’s market cap?

Astrazeneca Plc’s market cap is $212.97B.

When is Astrazeneca Plc’s upcoming earnings report date?

Astrazeneca Plc’s upcoming earnings report date is Jul 24, 2025 which is in 65 days.

How were Astrazeneca Plc’s earnings last quarter?

Astrazeneca Plc released its earnings results on Apr 29, 2025. The company reported $1.245 earnings per share for the quarter, beating the consensus estimate of $1.116 by $0.129.

Is Astrazeneca Plc overvalued?

According to Wall Street analysts Astrazeneca Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Astrazeneca Plc pay dividends?

Astrazeneca Plc pays a Semiannually dividend of $1.029 which represents an annual dividend yield of 2.21%. See more information on Astrazeneca Plc dividends here

What is Astrazeneca Plc’s EPS estimate?

Astrazeneca Plc’s EPS estimate is 1.1.

How many shares outstanding does Astrazeneca Plc have?

Astrazeneca Plc has 3,101,276,900 shares outstanding.

What happened to Astrazeneca Plc’s price movement after its last earnings report?

Astrazeneca Plc reported an EPS of $1.245 in its last earnings report, beating expectations of $1.116. Following the earnings report the stock price went up 2.545%.

Which hedge fund is a major shareholder of Astrazeneca Plc?

Currently, no hedge funds are holding shares in AZN

---

AstraZeneca Stock Smart Score

Outperform

Fundamentals

Return on Equity

19.81%

Trailing 12-Months

Asset Growth

3.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Astrazeneca Plc

AstraZeneca (AZN) is a global biopharmaceutical company engaged in the discovery, development, and commercialization of prescription medicines. Operating in over 100 countries, AstraZeneca focuses on three main therapeutic areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. The company is committed to delivering life-changing medicines and has a robust pipeline of innovative therapies.

---

AZN Company Deck

---

AZN Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong start to 2025 with significant revenue and EPS growth, driven by pipeline advancements and strategic global manufacturing. However, challenges such as Medicare Part D redesign and headwinds in China and Soliris revenue present areas of concern.Read More>

---

AZN Stock 12 Month Forecast

Average Price Target

$87.34

▲(25.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"63":"$63","72":"$72","81":"$81","90":"$90","99":"$99"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":98,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$98.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":87.34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$87.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$75.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[63,72,81,90,99],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.51,72.6246153846154,74.73923076923077,76.85384615384616,78.96846153846154,81.08307692307693,83.19769230769231,85.3123076923077,87.42692307692307,89.54153846153847,91.65615384615384,93.77076923076923,95.88538461538462,{"y":98,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.51,71.80461538461539,73.09923076923077,74.39384615384616,75.68846153846154,76.98307692307692,78.27769230769232,79.5723076923077,80.86692307692309,82.16153846153847,83.45615384615385,84.75076923076924,86.04538461538462,{"y":87.34,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.51,70.85538461538462,71.20076923076924,71.54615384615386,71.89153846153846,72.23692307692308,72.5823076923077,72.92769230769231,73.27307692307693,73.61846153846155,73.96384615384615,74.30923076923077,74.65461538461538,{"y":75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":74.9,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.48,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.4,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.6,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.41,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.58,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.43,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.11,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.78,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.21,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.51,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >